When I turned 50, I weighed 265 pounds. Over the next 12 years, through walking, yoga, and strength training, I lost 60 pounds and kept it off. But despite the discipline, I remained plagued by inflammation, pain, and sleep apnea.
Then last year, my doctor suggested tirzepatide (Zepbound), not just for weight loss but to treat my sleep apnea as well. That alternative diagnosis unlocked insurance coverage and led to a life-changing outcome. Within 12 months, I lost another 60 pounds, reduced visceral fat, lowered inflammation, improved muscle mass, and finally became pain free.
This was not a shortcut; it was a catalyst. The GLP‑1 quieted my food noise and gave me the mental clarity to sustain daily movement and nutrition protocols that had previously stalled on their own.
Stories like mine, including those of people such as a woman in perimenopause managing glucose swings, emphasize that GLP‑1 drugs are metabolic tools, not vanity fixes. Yet far too many insurers still deny coverage based on outdated BMI thresholds or narrow weight-loss criteria.
These medications offer more than slimmer bodies:
- Regulated A1C and daily blood sugar control
- Reduced inflammation and better sleep
- Improved functionality across age groups
Many physicians are finding success obtaining coverage for GLP‑1s using diagnoses such as insulin resistance (E88.81), sleep apnea (G47.33), metabolic syndrome, or PCOS (E28.2), especially when documented alongside prediabetes, hypertension, or cardiovascular risk factors. These are real, treatable conditions that respond well to GLP‑1 therapy, even if the patient’s BMI does not qualify them under outdated obesity metrics. Broader acceptance of these diagnoses for coverage could help close the access gap and bring meaningful metabolic care to people who are otherwise left behind.
As board chair of a nonprofit health plan, a retired Deloitte partner, and a yoga instructor, I have seen how outdated coding practices and BMI-focused policies leave many capable people locked out of effective care.
We need a shift. GLP‑1 medications should be framed as tools for equity in metabolic health, prescribed based on insulin resistance, prediabetes, sleep apnea, or age-related visceral fat, not just weight.
GLP‑1s are not magic pills. However, when paired with intention, movement, and protein-forward nutrition, they are among the most potent tools for unlocking health, especially when access is fair and equitable.
Rodney Lenfant is a patient advocate.
